ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Equities research analysts at Leerink Swann increased their FY2017 earnings estimates for ACADIA Pharmaceuticals in a note issued to investors on Tuesday. Leerink Swann analyst P. Matteis now anticipates that the biopharmaceutical company will post earnings per share of ($2.38) for the year, up from their previous forecast of ($2.53). Leerink Swann has a “Market Perform” rating on the stock. Leerink Swann also issued estimates for ACADIA Pharmaceuticals’ Q4 2017 earnings at ($0.57) EPS, Q2 2018 earnings at ($0.50) EPS, Q3 2018 earnings at ($0.45) EPS, Q4 2018 earnings at ($0.41) EPS, FY2018 earnings at ($1.92) EPS, FY2019 earnings at ($1.49) EPS and FY2020 earnings at ($0.35) EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.10. The company had revenue of $35.58 million during the quarter, compared to analysts’ expectations of $32.03 million. ACADIA Pharmaceuticals had a negative net margin of 320.71% and a negative return on equity of 67.68%. ACADIA Pharmaceuticals’s revenue for the quarter was up 571.3% on a year-over-year basis. During the same period last year, the business earned ($0.61) EPS.

ILLEGAL ACTIVITY WARNING: “FY2017 EPS Estimates for ACADIA Pharmaceuticals Inc. Lifted by Analyst (ACAD)” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/12/fy2017-eps-estimates-for-acadia-pharmaceuticals-inc-lifted-by-analyst-acad.html.

Other analysts have also recently issued reports about the stock. Ladenburg Thalmann Financial Services restated a “buy” rating and set a $50.00 price objective (up from $48.00) on shares of ACADIA Pharmaceuticals in a research note on Monday, October 2nd. Needham & Company LLC restated a “buy” rating and set a $49.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Sunday, September 17th. Goldman Sachs Group, Inc. (The) restated a “neutral” rating and set a $45.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Friday, October 6th. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Wednesday, August 9th. Finally, Cowen and Company reaffirmed a “buy” rating and set a $46.00 target price on shares of ACADIA Pharmaceuticals in a report on Tuesday, November 7th. Six investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $47.73.

Shares of ACADIA Pharmaceuticals (ACAD) opened at $28.60 on Friday. ACADIA Pharmaceuticals has a 12 month low of $24.31 and a 12 month high of $41.20.

A number of large investors have recently modified their holdings of ACAD. Teachers Advisors LLC increased its stake in ACADIA Pharmaceuticals by 2.2% during the first quarter. Teachers Advisors LLC now owns 125,022 shares of the biopharmaceutical company’s stock worth $4,298,000 after purchasing an additional 2,722 shares during the period. PNC Financial Services Group Inc. increased its stake in ACADIA Pharmaceuticals by 138.8% during the first quarter. PNC Financial Services Group Inc. now owns 4,384 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 2,548 shares during the period. Legal & General Group Plc increased its stake in ACADIA Pharmaceuticals by 173.5% during the first quarter. Legal & General Group Plc now owns 32,968 shares of the biopharmaceutical company’s stock worth $1,133,000 after purchasing an additional 20,916 shares during the period. Dimensional Fund Advisors LP increased its stake in ACADIA Pharmaceuticals by 2,500.1% during the first quarter. Dimensional Fund Advisors LP now owns 198,620 shares of the biopharmaceutical company’s stock worth $6,828,000 after purchasing an additional 190,981 shares during the period. Finally, BlackRock Inc. increased its stake in ACADIA Pharmaceuticals by 5,422.8% during the first quarter. BlackRock Inc. now owns 5,433,209 shares of the biopharmaceutical company’s stock worth $186,791,000 after purchasing an additional 5,334,832 shares during the period. Institutional investors own 97.01% of the company’s stock.

In other ACADIA Pharmaceuticals news, EVP Glenn Baity sold 37,500 shares of the company’s stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $40.91, for a total value of $1,534,125.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 22.25% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Earnings History and Estimates for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Stock Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.